The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: Data from multicenter, prospective, longitudinal clinic practice

Journal of Psychiatric Research

Volumn 47, Issue 1, 2013, Pages 8-14

  Li, Zezhi ^a,b   Zhang, Yanxia ^a   Wang, Zuowei ^a   Chen, Jun ^a   Fan, Jinbo ^c   Guan, Yangtai ^b   Zhang, Chen ^a   Yuan, Chengmei ^a   Hong, Wu ^a   Wang, Yong ^a   Wu, Zhiguo ^a   Huang, Jia ^a   Hu, Yingyan ^a   Cao, Lan ^a   Yi, Zhenghui ^a   Cui, Donghong ^a   Yu, Shunying ^a   Fang, Yiru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BDNF; Interaction; NTRK2; Treatment resistant depression

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MULTIFACTOR DIMENSIONALITY REDUCTION; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

EID: 84869878797     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.10.003     Document Type: Article

References (45)

1. Anttila S., Huuhka K., Huuhka M., Rontu R., Hurme M., Leinonen E., et al. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. Journal of Neural Transmission 2007, 114:1065-1068.
2. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment resistant refractory major depression: a review of current concepts and methods. Canadian Journal of Psychiatry 2007, 52:46-54.
3. Blugeot A., Rivat C., Bouvier E., Molet J., Mouchard A., Zeau B., et al. Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. Journal of Neuroscience 2011, 31:12889-12899.
4. Bremer T., Diamond C., McKinney R., Shehktman T., Barrett T.B., Herold C., et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Molecular Diagnosis & Therapy 2007, 11:161-170.
5. Burmeister M., McInnis M.G., Zollner S. Psychiatric genetics: progress amid controversy. Nature Reviews Genetics 2008, 9:527-540.
6. Choi M.J., Kang R.H., Lim S.W., Oh K.S., Lee M.S. Brain-derived neurotrophic factor gene polymorphism (val66met) and citalopram response in major depressive disorder. Brain Research 2006, 1118:176-182.
7. Dervieux T., Wessels J.A., Kremer J.M., Padyukov L., Seddighzadeh M., Saevarsdottir S., et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenetics and Genomics 2012, 22:1-9.
8. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Medicine 2004, 5:11-25.
9. Dunham J.S., Deakin J.F., Miyajima F., Payton A., Toro C.T. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. Journal of Psychiatric Research 2009, 43:1175-1184.
10. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
11. Fang Y.R., Yuan C.M., Xu Y.F., Chen J., Wu Z.G., Cao L., et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression a double-blind, randomized pilot study in a Chinese population. Journal of Clinical Psychopharmacology 2010, 30:357-364.
12. Fang Y.R., Yuan C.M., Xu Y.F., Chen J., Wu Z.G., Cao L., et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of Clinical Psychopharmacology 2011, 31:638-642.
13. Fernandes B.S., Gama C.S., Ceresér K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. Journal of Psychiatric Research 2011, 45:995-1004.
14. Gauderman W.J., Morrison J.M. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies 2006, http://hydra.usc.edu/gxe.
15. Gibson T.B., Jing Y., Smith Carls G., Kim E., Bagalman J.E., Burton W.N., et al. Cost burden of treatment resistance in patients with depression. American Journal of Managed Care 2010, 16:370-377.
16. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Research Reviews 2004, 45:104-114.
17. Kang R., Chang H., Wong M., Choi M., Park J., Lee H., et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology 2010, 24:1755-1763.
18. Kayser S., Bewernick B.H., Grubert C., Hadrysiewicz B.L., Axmacher N., Schlaepfer T.E. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. Journal of Psychiatric Research 2011, 45:569-576.
19. Laje G., McMahon F.J. The pharmacogenetics of major depression: past, present, and future. Biological Psychiatry 2007, 62:1205-1207.
20. Li Z., Qi D., Chen J., Zhang C., Yi Z., Yuan C., et al. Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: a prospective longitudinal study. Psychoneuroendocrinology 2012, Epub ahead of print. http://dx.doi.org/10.1016/j.psyneuen.2012.05.005.
21. O'Reilly R.L., Bogue L., Singh S.M. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry 1994, 36:467-471.
22. Obergriesser T., Ende G., Braus D.F., Henn F.A. Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. Journal of Clinical Psychiatry 2003, 64:775-780.
23. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. Journal of Neuroscience 2004, 24:10099-10102.
24. Piccinni A., Del Debbio A., Medda P., Bianchi C., Roncaglia I., Veltri A., et al. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. European Neuropsychopharmacology 2009, 19:349-355.
25. Ritchie M.D., Hahn L.W., Roodi N., Bailey L.R., Dupont W.D., Parl F.F., et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. American Journal of Human Genetics 2001, 69:138-147.
26. Rush A.J., Thase M.E., Dube S. Research issues in the study of difficult-to-treat depression. Biological Psychiatry 2003, 53:743-753.
27. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 2006, 163:1905-1917.
28. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. Journal of Neuroscience 2003, 23:349-357.
29. Scott J., Dickey B. Global burden of depression: the intersection of culture and medicine. British Journal of Psychiatry 2003, 183:92-94.
30. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., et al. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of Affective Disorders 2011, 128:56-63.
31. Shah P.J., Glabus M.F., Goodwin G.M., Ebmeier K.P. Chronic, treatment-resistant depression and right fronto-striatal atrophy. British Journal of Psychiatry 2002, 180:434-440.
32. Shelton R.C., Osuntokun O., Heinloth A.N., Corya S.A. Therapeutic options for treatment-resistant depression. CNS Drugs 2010, 24:131-161.
33. Sillaber I., Panhuysen M., Henniger M.S., Ohl F., Kühne C., Pütz B., et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berlin) 2008, 200:557-572.
34. Smith E.N., Bloss C.S., Badner J.A., Barrett T., Belmonte P.L., Berrettini W., et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Molecular Psychiatry 2009, 14:755-763.
35. Squinto S.P., Stitt T.N., Aldrich T.H., Davis S., Bianco S.M., Radziejewski C., et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 1991, 65:885-893.
36. Taylor S.M. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. Journal of ECT 2008, 24:160-165.
37. The International HapMap Consortium Integrating common and rare genetic variation in diverse human populations. Nature 2010, 467:52-58.
38. Toups M.S., Greer T.L., Kurian B.T., Grannemann B.D., Carmody T.J., Huebinger R., et al. Effects of serum brain derived neurotrophic factor on exercise augmentation treatment of depression. Journal of Psychiatric Research 2011, 45:1301-1306.
39. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. American Journal of Medical Genetics 2003, 123B:19-22.
40. Vieta E., Colom F. Therapeutic options in treatment-resistant depression. Annals of Medicine 2011, 43:512-530.
41. Wang Z., Li Z., Gao K., Fan J., Wang L., Huang J., et al. Association of BDNF gene polymorphism with bipolar disorder in Han Chinese population. Genes, Brain and Behavior 2012 Apr 30, Epub ahead of print. 10.1111/j.1601-183X.2012.00797.x.
42. Xu H., Chen Z., He J., Haimanot S., Li X., Dyck L., et al. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006, 16:551-559.
43. Yukimasa T., Yoshimura R., Tamagawa A., Uozumi T., Shinkai K., Ueda N., et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 2006, 39:52-59.
44. Zou Y.F., Wang Y., Liu P., Feng X.L., Wang B.Y., Zang T.H., et al. Association of brain-derived neurotrophic factor genetic val66met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology 2010, 61:71-78.
45. Zou Y.F., Ye D.Q., Feng X.L., Su H., Pan F.M., Liao F.F. Meta-analysis of BDNF val66met polymorphism association with treatment response in patients with major depressive disorder. European Neuropsychopharmacology 2010, 20:535-544.